Immune priming in invertebrates refers to an improved immune response (and therefore a better chance of survival) upon a second encounter with a specific pathogen. Although the existence of immune priming has been evaluated in invertebrate hosts, the ability of a particular entomopathogen species or strain to influence the occurrence of immune priming has not been thoroughly evaluated. The aim of the current study was to compare the occurrence of immune priming in Tenebrio molitor larvae after homologous challenges (a dual exposure to similar entomopathogens) with Serratia marcescens, Bacillus thuringiensis and Metarhizium anisopliae. Larvae presented more effective immune priming (measured as survival rates) when exposed to M. anisopliae or B. thuringiensis than when exposed to S. marcescens. We hypothesize that the toll pathway may help T. molitor survive these enemies and that the IMD pathway may be expressed to a lesser degree in this species, which may explain why they succumb to Gram-negative bacteria. This and other recent evidence suggest that the occurrence of immune priming in these organisms must not be ruled out until this phenomenon is tested with different entomopathogens.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.micpath.2018.03.063 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
HIFU-CCL19/21 Axis Enhances Dendritic Cell Vaccine Efficacy in the Tumor Microenvironment.
Pharmaceutics
January 2025
Wide River Institute of Immunology, Seoul National University College of Medicine, Hongcheon 25159, Gangwon, Republic of Korea.
Background/objectives: Effectively targeting treatment-resistant tumor cells, particularly cancer stem cells (CSCs) involved in tumor recurrence, remains a major challenge in immunotherapy. This study examines the potential of combining mechanical high-intensity focused ultrasound (M-HIFU) with dendritic cell (DC) vaccines to enhance immune responses against OLFM4-expressing tumors, a CSC marker linked to immune evasion and tumor growth.
Methods: M-HIFU was applied to induce immunogenic cell death by mechanically disrupting tumor cells, releasing tumor-associated antigens and creating an immunostimulatory environment.
Comparison of Vaccination Regimens on Immune Responses Using PED Replicon Vaccine: A Field Trial in PED-Negative and PED-Positive Thai Swine Farms.
Animals (Basel)
January 2025
Department of Veterinary Pathology, Faculty of Veterinary Science, Chulalongkorn University, Bangkok 10330, Thailand.
Porcine epidemic diarrhea virus (PEDV) is an economically important pathogen of swine, causing severe diarrhea in neonates with high morbidity and mortality. Vaccination is a key strategy for PEDV control, but optimizing regimens based on herd status is essential for improving immunity and protection. This study evaluated immune responses to different vaccination protocols using a PED replicon vaccine (PED-RP) in Thai swine farms with varying PED statuses.
View Article and Find Full Text PDFFollicular lymphoma (FL) outcomes are heavily influenced by host immune activity with immune anti-tumor activity mitigated by PD-1/PD-L1 pathway engagement. Combination CD20-directed therapy plus PD-1 inhibition (PD-1i) increases T-cell tumor killing and NK-cell antibody-dependent cell cytotoxicity (ADCC). Mounting evidence supports immune-priming using PD-1i before cancer-directed agents.
View Article and Find Full Text PDFAdenoviral Vector-Based Vaccine Expressing Hemagglutinin Stem Region with Autophagy-Inducing Peptide Confers Cross-Protection Against Group 1 and 2 Influenza A Viruses.
Vaccines (Basel)
January 2025
Department of Comparative Pathobiology, Purdue Institute of Inflammation, Immunology and Infectious Disease, College of Veterinary Medicine, Purdue University, 625 Harrison St., West Lafayette, IN 47907, USA.
An effective universal influenza vaccine is urgently needed to overcome the limitations of current seasonal influenza vaccines, which are ineffective against mismatched strains and unable to protect against pandemic influenza. In this study, bovine and human adenoviral vector-based vaccine platforms were utilized to express various combinations of antigens. These included the H5N1 hemagglutinin (HA) stem region or HA2, the extracellular domain of matrix protein 2 of influenza A virus, HA signal peptide (SP), trimerization domain, excretory peptide, and the autophagy-inducing peptide C5 (AIP-C5).
View Article and Find Full Text PDFAnti-Idiotypic Antibody as a Booster Vaccine Against Respiratory Syncytial Virus.
Vaccines (Basel)
January 2025
Infectious Diseases and Vaccine Research, Merck & Co., Inc., Rahway, NJ 07065, USA.
The respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections in children and adults. With nearly everyone infected by the age of five, there is an opportunity to develop booster vaccines that enhance B-cell immunity, promoting potent and broadly neutralizing antibodies. One potential approach involves using anti-idiotypic antibodies (anti-IDs) to mimic specific antigenic sites and enhance preexisting immunity in an epitope-specific manner.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!